4//SEC Filing
TETRALOGIC PHARMACEUTICALS CORP 4
Accession 0001012975-16-000980
CIK 0001361248operating
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 8:39 PM ET
Size
24.6 KB
Accession
0001012975-16-000980
Insider Transaction Report
Form 4
Clarus Lifesciences II, L.P.
10% Owner
Transactions
- Sale
Common Stock
2016-02-05$0.20/sh−832,881$166,576→ 2,548,153 total - Sale
Common Stock
2016-02-03$0.15/sh−82,583$12,387→ 3,881,060 total - Sale
Common Stock
2016-02-04$0.14/sh−500,026$70,004→ 3,381,034 total
Clarus Ventures II GP, L.P.
10% Owner
Transactions
- Sale
Common Stock
2016-02-03$0.15/sh−82,583$12,387→ 3,881,060 total - Sale
Common Stock
2016-02-04$0.14/sh−500,026$70,004→ 3,381,034 total - Sale
Common Stock
2016-02-05$0.20/sh−832,881$166,576→ 2,548,153 total
Clarus Ventures II, LLC
10% Owner
Transactions
- Sale
Common Stock
2016-02-03$0.15/sh−82,583$12,387→ 3,881,060 total - Sale
Common Stock
2016-02-04$0.14/sh−500,026$70,004→ 3,381,034 total - Sale
Common Stock
2016-02-05$0.20/sh−832,881$166,576→ 2,548,153 total
GALAKATOS NICHOLAS
10% Owner
Transactions
- Sale
Common Stock
2016-02-03$0.15/sh−82,583$12,387→ 3,881,060 total - Sale
Common Stock
2016-02-04$0.14/sh−500,026$70,004→ 3,381,034 total - Sale
Common Stock
2016-02-05$0.20/sh−832,881$166,576→ 2,548,153 total
HENNER DENNIS
10% Owner
Transactions
- Sale
Common Stock
2016-02-03$0.15/sh−82,583$12,387→ 3,881,060 total - Sale
Common Stock
2016-02-04$0.14/sh−500,026$70,004→ 3,381,034 total - Sale
Common Stock
2016-02-05$0.20/sh−832,881$166,576→ 2,548,153 total
LIPTAK ROBERT
10% Owner
Transactions
- Sale
Common Stock
2016-02-03$0.15/sh−82,583$12,387→ 3,881,060 total - Sale
Common Stock
2016-02-04$0.14/sh−500,026$70,004→ 3,381,034 total - Sale
Common Stock
2016-02-05$0.20/sh−832,881$166,576→ 2,548,153 total
Simon Nicholas
10% Owner
Transactions
- Sale
Common Stock
2016-02-03$0.15/sh−82,583$12,387→ 3,881,060 total - Sale
Common Stock
2016-02-04$0.14/sh−500,026$70,004→ 3,381,034 total - Sale
Common Stock
2016-02-05$0.20/sh−832,881$166,576→ 2,548,153 total
STEINMETZ MICHAEL
Director10% Owner
Transactions
- Sale
Common Stock
2016-02-03$0.15/sh−82,583$12,387→ 3,881,060 total - Sale
Common Stock
2016-02-04$0.14/sh−500,026$70,004→ 3,381,034 total - Sale
Common Stock
2016-02-05$0.20/sh−832,881$166,576→ 2,548,153 total
WHEELER KURT
10% Owner
Transactions
- Sale
Common Stock
2016-02-05$0.20/sh−832,881$166,576→ 2,548,153 total - Sale
Common Stock
2016-02-03$0.15/sh−82,583$12,387→ 3,881,060 total - Sale
Common Stock
2016-02-04$0.14/sh−500,026$70,004→ 3,381,034 total
Footnotes (4)
- [F1]The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $.15 to $.16 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F2]The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $.14 to $.15 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $.15 to $.23 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]Securities held of record by Clarus Lifesciences II, L.P. ("Clarus"). Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of the GPLLC and Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which it or he, as applicable, does not have an actual pecuniary interest.
Documents
Issuer
TETRALOGIC PHARMACEUTICALS CORP
CIK 0001361248
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001361248
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 8:39 PM ET
- Size
- 24.6 KB